MedTrace Logo

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

NCT03712787 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 364

Last updated 2022-09-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.

Conditions

Interventions

DRUG

Tilavonemab

solution for IV infusion

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
57 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Denmark
  • Finland
  • Italy
  • New Zealand
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03712787 on ClinicalTrials.gov